CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)

N Reinmuth, L Paz-Ares,Y Chen, K Hotta, D Trukhin, G Statsenko, MJ Hochmair,M Özgüroğlu, J Ho Li, O Voitko, A Poltoratskiy,S Ponce, F Verderame,L Havel,I Bondarenko, A Kazarnowicz, G Losonczy,NV Conev, J Armstrong, N Byrne, N Shire,H Jiang, J Goldman, J Alt

user-5f8cf7e04c775ec6fa691c92（2020）

引用 0|浏览16

暂无评分

关键词

Durvalumab,Tremelimumab,Extensive stage,Chemotherapy,Oncology,Medicine,First line,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要